EUVIMEDEUVIMED entdecken
Crossref

PET Imaging of Thyroid-Stimulating Hormone Receptor (TSHR) in Oncocytic Thyroid Carcinoma for Monitoring TSHR CAR T-Cell Therapy Response

Wenhui Fu, Ephraim E Parent, Justyna J Gleba, Joshua A Knight, Saad J Kenderian, John A Copland, Hancheng Cai iD

Bioconjugate Chemistry · 2025

DOI: 10.1021/acs.bioconjchem.5c00235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Wenhui Fu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Mayo Clinic, Jacksonville, Florida 32224, United States. Hauptthemen laut MEDLINE: Receptors, Thyrotropin, Thyroid Neoplasms, Positron-Emission Tomography, Receptors, Chimeric Antigen. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Mayo Clinic, Florida State Funds for the Casey DeSantis Cancer Research Program, Mayo Clinic Center for Biomedical Discovery Pilot.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncocytic thyroid carcinoma (OTC) is often aggressive and refractory to radioiodine therapy, which is the current standard of care for metastatic thyroid cancer. The thyroid-stimulating hormone receptor (TSHR) regulates thyroid function and metabolism and is highly expressed in the thyroid gland and most thyroid tumors including OTC. Here, we report positron emission tomography (PET) imaging of radiolabeled TSHR antibody for detecting tumoral TSHR expression and monitoring TSHR chimeric antigen receptor (CAR) T-cell therapy response in an OTC mouse model. Radiotracer 89Zr-DFO-TSHR-Ab was prepared as previously reported for PET imaging of TSHR expression. Tissue microarray analysis confirmed TSHR expression in both normal thyroid and OTC tumors. A human OTC xenograft model was established by subcutaneous injection of XTC.UC1 cells into NSG mice. PET imaging and biodistribution studies of TSHR expression were subsequently conducted in this model to assess TSHR-expression change before and after TSHR CAR T-cell therapy. TSHR-targeted CAR T-cells were administered intravenously, and longitudinal PET/CT imaging with 89Zr-DFO-TSHR-Ab was performed at 24, 72, and 120 h postinjection to monitor tumor response. Eight weeks later, the same mice were rechallenged with XTC.UC1 cells in the contralateral flank to assess long-term therapeutic efficacy and immune memory through serial PET/CT imaging. PET imaging and biodistribution studies demonstrated that this radiotracer effectively detected TSHR-expressing OTC, with reasonable tumor uptake and imaging contrast. Following CAR T-cell therapy, TSHR PET showed significantly decreased tumor uptake, consistent with TSHR-targeted cell immunotherapy response with attenuated TSHR expression. These findings suggest 89Zr-DFO-TSHR-Ab enables noninvasive identification of OTC tumors and real-time monitoring of response to TSHR-targeted CAR T-cell therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ThyrotropinThyroid NeoplasmsPositron-Emission TomographyReceptors, Chimeric AntigenImmunotherapy, AdoptiveAnimalsHumansMiceCell Line, TumorTissue DistributionRadioisotopesZirconium

Substanzen

Receptors, ThyrotropinReceptors, Chimeric AntigenRadioisotopesZirconium

Autor:innen und Institutionen

  • Department of Radiology, Mayo Clinic, Jacksonville, Florida 32224, United States.
  • Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida 32224, United States.
  • Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, United States.
  • Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905, United States.
  • Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, United States.

ORCID-Profile: Hancheng Cai

Förderung

  • Mayo Clinic
  • Florida State Funds for the Casey DeSantis Cancer Research Program
  • Mayo Clinic Center for Biomedical Discovery Pilot
  • Mayo Clinic Florida Radiology Research

Zitieren

APA

Fu, W., Parent, E. E., Gleba, J. J., Knight, J. A., Kenderian, S. J., Copland, J. A., & Cai, H. (2025). PET Imaging of Thyroid-Stimulating Hormone Receptor (TSHR) in Oncocytic Thyroid Carcinoma for Monitoring TSHR CAR T-Cell Therapy Response. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00235

Vancouver

Fu W, Parent EE, Gleba JJ, Knight JA, Kenderian SJ, Copland JA, et al. PET Imaging of Thyroid-Stimulating Hormone Receptor (TSHR) in Oncocytic Thyroid Carcinoma for Monitoring TSHR CAR T-Cell Therapy Response. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00235

BibTeX
@article{Fu2025,
  author = {Fu, Wenhui and Parent, Ephraim E and Gleba, Justyna J and Knight, Joshua A and Kenderian, Saad J and Copland, John A and Cai, Hancheng},
  title = {PET Imaging of Thyroid-Stimulating Hormone Receptor (TSHR) in Oncocytic Thyroid Carcinoma for Monitoring TSHR CAR T-Cell Therapy Response},
  journal = {Bioconjugate Chemistry},
  year = {2025},
  doi = {10.1021/acs.bioconjchem.5c00235}
}
Kostenlos starten →